Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model

Recently, several types of systemic therapy using tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) have been performed for advanced renal cell carcinoma (aRCC) patients; however, the optimal strategy of sequential treatment with these agents has not been well established. The ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Hiromitsu, Matsushita, Yuto, Tamura, Keita, Motoyama, Daisuke, Sugiyama, Takayuki, Otsuka, Atsushi, Miyake, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344912/
https://www.ncbi.nlm.nih.gov/pubmed/37443122
http://dx.doi.org/10.1038/s41598-023-37857-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344912/
https://www.ncbi.nlm.nih.gov/pubmed/37443122
http://dx.doi.org/10.1038/s41598-023-37857-9

Ejemplares similares